320 related articles for article (PubMed ID: 21440964)
1. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
[TBL] [Abstract][Full Text] [Related]
2. Conversion of protein farnesyltransferase to a geranylgeranyltransferase.
Terry KL; Casey PJ; Beese LS
Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
4. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces.
Machida S; Usuba K; Blaskovich MA; Yano A; Harada K; Sebti SM; Kato N; Ohkanda J
Chemistry; 2008; 14(5):1392-401. PubMed ID: 18200641
[TBL] [Abstract][Full Text] [Related]
5. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
Yang W; Del Villar K; Urano J; Mitsuzawa H; Tamanoi F
J Cell Biochem Suppl; 1997; 27():12-9. PubMed ID: 9591188
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Shen M; Pan P; Li Y; Li D; Yu H; Hou T
Drug Discov Today; 2015 Feb; 20(2):267-76. PubMed ID: 25450772
[TBL] [Abstract][Full Text] [Related]
7. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Reid TS; Terry KL; Casey PJ; Beese LS
J Mol Biol; 2004 Oct; 343(2):417-33. PubMed ID: 15451670
[TBL] [Abstract][Full Text] [Related]
8. Theoretical studies on binding and specificity mechanisms of farnesyltransferase (FTase) and geranylgeranyltransferase type-I (GGTase-I) inhibitors by molecular modeling.
Zhou S
Comb Chem High Throughput Screen; 2014; 17(6):509-19. PubMed ID: 24444014
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
[TBL] [Abstract][Full Text] [Related]
10. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I.
Carrico D; Blaskovich MA; Bucher CJ; Sebti SM; Hamilton AD
Bioorg Med Chem; 2005 Feb; 13(3):677-88. PubMed ID: 15653335
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.
Li Q; Woods KW; Wang W; Lin NH; Claiborne A; Gu WZ; Cohen J; Stoll VS; Hutchins C; Frost D; Rosenberg SH; Sham HL
Bioorg Med Chem Lett; 2005 Apr; 15(8):2033-9. PubMed ID: 15808463
[TBL] [Abstract][Full Text] [Related]
14. Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
Bergman JM; Abrams MT; Davide JP; Greenberg IB; Robinson RG; Buser CA; Huber HE; Koblan KS; Kohl NE; Lobell RB; Graham SL; Hartman GD; Williams TM; Dinsmore CJ
Bioorg Med Chem Lett; 2001 Jun; 11(11):1411-5. PubMed ID: 11378366
[TBL] [Abstract][Full Text] [Related]
15. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
[TBL] [Abstract][Full Text] [Related]
16. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
18. Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.
Bolchi C; Pallavicini M; Bernini SK; Chiodini G; Corsini A; Ferri N; Fumagalli L; Straniero V; Valoti E
Bioorg Med Chem Lett; 2011 Sep; 21(18):5408-12. PubMed ID: 21802946
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of Non-natural, Frame-Shifted Isoprenoid Diphosphate Analogues.
Temple KJ; Wright EN; Fierke CA; Gibbs RA
Org Lett; 2016 Dec; 18(23):6038-6041. PubMed ID: 27934359
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
